Par CEO replaced
Patrick LePore takes over as president and CEO of Par Pharmaceutical following resignation of Scott Tariff at the request of the board of directors, the company announces Sept. 26. Executive chairman Mark Auerbach also steps down at board's request; former lead director John Abernathy will fill the role as non-executive chairman. LePore worked in sales and marketing at Roche from 1978 to 1984; in 2002, he oversaw the sale of medical communications company Boron LaPore & Associates to Cardinal Health. Par announced in July that it would be restating its financial results for 2004 through the first quarter of 2006, reducing Par's revenues over that time period by as much as $55 mil...
You may also be interested in...
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.